Board members

Andrew Midler

Chairman, Investor

Mr. Midler is the Founder and Managing Member of Savitr Capital, LLC. Previously, he was the Founder, Chief Exetuive Officer and Chief Investment Officer of Standard Pacific Capital, LLC.

Alex Drijver

Alex Drijver is the CEO of ChemAxon, a leader in providing chemical software development platforms for the biotechnology and pharmaceutical industries. Mr. Drijver was a founder and former CEO of ThalesNano. He had a number of operating roles at the company between 2002-2007. Drijver overseas all strategic financial matters for the company. Earlier he was Chief Financial Officer at ComGenex Inc. and Vice President of ABN AMRO Bank in London, and then Budapest. Before joining to ABN AMRO, Drijver worked in different financial and investment related positions in London for 10 years. He is the holder of the R&D 100's Award and the Hungarian Venture Capital Association’s SME of the Year Award.
Leslie D. Michelson

Lynne Powell


Ms. Powell has more than 25 years’ experience in the biopharmaceutical/ biotechnology industry.  Prior to DRGT she served as Chief Commercial Office at BioCryst, an emerging biotechnology company focused on commercializing innovative small molecules. Before this, she was Senior Vice President, North America, at CSL Behring.  Throughout her 17-year career at CSL Behring, she assumed increasing responsibilities within the R&D and commercial functions of the organization. Lynne has significant global experience serving as Vice President, Global Commercial Development and Head of Business Development & European Marketing, Head of Project and Portfolio Management and Head of Clinical Research. Ms. Powell also held positions within Glaxo Wellcome’s commercial strategy and clinical research organizations.

Lyenne Powell